Background: The present study investigated whether CHA2DS2-VASc score in patients with NVAF suffering from non-cerebral thromboembolism is different from those suffering stroke. Methods: The present study retrospectively reviewed medical records of 213 patients with NVAF who experienced stroke, and 115 patients with NVAF who experienced non-cerebral thromboembolism between 2010 and 2015. In all patients, CHA2DS2-VASc score before the event was calculated. Results: The mean CHA2DS2-VASc score was higher in patients with stroke (4.52±1.66) than those with non-cerebral thromboembolism (4.29±2.02) (p=0.013). In-hospital mortality rate was similar between the groups (19% vs. 17%, p=0.756) . The rates of coronary artery disease (52% vs. 38%, p=0.014), prior ischemic attack (16% vs. 5%, p=0.001), and prior non-cerebral thromboembolism (18% vs. 3%, p<0.001) were higher in patients with non-cerebral thromboembolism. Warfarin (55% vs. 14% p<0.001) and antiplatelet use (56% vs. 40%, p=0.004) was more common in the non-cerebral embolism group, while non-vitamin K antagonist oral anticoagulant (NOAC) use was more common in the stroke group (15% vs. 7% p=0.026). Conclusion: The patients with stroke had higher CHA2DS2-VASc scores compared to patients with non-cerebral thromboembolism